TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06576921
Drug: Serplulimab Combined With Chemotherapy
Normalized name: miconazole
DrugBank: Serplulimab (DB17451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Serplulimab (Dosage form: Lyophilized powder; Unit dose strength: 4.5 mg; Route of administration: IV infusion; Storage requirements: 2-8℃. Protect from light and freezing.) Nap-paclitaxel (Dosage form: Lyophilized powder; Unit dose strength: 100 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) S-1 (Dosage form: Capsule; Unit dose strength: 20 mg; Route of administration: Oral; Storage requirements: 20-30℃. Protect from light.) Oxaliplatin (Dosage form: Lyophilized powder; Unit dose strength: 50 mg; Route of administration: IV infusion; Storage requirements: \<25℃. Protect from light.) Surgery: All surgical procedures are performed according to the guidelines of the Japanese Research Society for the Study of Gastric Cancer.
Study: NCT04685590
Drug: Dasatinib + Quercetin
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: D+Q will be administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
Study: NCT05840016
Drug: AK112, Carboplatin, Paxlitaxel
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion,Specified dose on specified days
Study: NCT05840016
Drug: Tislelizumab, Carboplatin, Paxlitaxel
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion,Specified dose on specified days
Study: NCT06336707
Drug: HS-20089
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04230148
Drug: Egaten (Triclabendazole) 250 mg tablets
Normalized name: Egaten
DrugBank: Triclabendazole (DB12245)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Egaten 250 mg scored tablets for oral use.
Study: NCT06336707
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT06336707
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infusion
Study: NCT06336707
Drug: Cisplatin / carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04657224
Drug: JNJ-64264681
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64264681 capsules will be administered orally.
Study: NCT04657224
Drug: JNJ-67856633
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-67856633 capsules or tablets will be administered orally.
Study: NCT05022927
Drug: Tocilicumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab vial
Study: NCT05022927
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab vial
Study: NCT05022927
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab vial
Study: NCT05073835
Drug: Semaglutide 3 mg
Normalized name: semaglutide 3 MG
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).
Study: NCT00000841
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000841
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00000841
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000841
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06454240
Drug: lunsekimig
Normalized name: Lunsekimig
DrugBank: Lunsekimig (DB19009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection-Route of administration:subcutaneous
Study: NCT06646978
Drug: Imatinib (STI571)
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib-based regimen
Study: NCT06367426
Drug: DDN-A-0101 (SAD)
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational drug~* Development name: DDN-A-0101~* Main ingredient and content: DDN-A-0101 (Houttuynia cordata dry extract, 150.0 mg)~* Formulation and properties: Light brown circular film coating tablet~* Storage method: airtight container, stored at room temperature (1-30 degree celsius)~* Administration method: single dose oral administration (300, 600, 900, 1200, 1500 mg)~* Expiration date: 36 months from the date of manufacture
Study: NCT05132595
Drug: Esketamine at high dose
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the induction of anesthesia, esketamine is intravenously injected at 0.4mg/kg, and then a continuous infusion of 0.4mg/kg/h esketamine until starting skin suture.
Study: NCT06112743
Drug: Mavacamten
Normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05132595
Drug: Esketamine at low dose
Normalized name: esketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the induction of anesthesia, esketamine is intravenously injected at 0.2mg/kg, and then a continuous infusion of 0.2mg/kg/h esketamine until starting skin suture.
Study: NCT00000997
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06413745
Drug: SHR-A1811
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811
Study: NCT06416969
Drug: Somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion 200 ug/hr for 2 hours, 100 ug/hr for 30 minutes
Study: NCT06505278
Drug: Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide between 10:00 pm and 12:00 pm in the evening.
Study: NCT05698888
Drug: VP301
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.
Study: NCT05960149
Drug: using Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nerve-sparing robot-assisted laparoscopic radical prostatectomy using Indocyanine Green
Study: NCT05519072
Drug: Nitrofurantoin
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For those randomized to the treatment arm, antibiotics will be prescribed at the discretion of the ordering physician. They will be prescribed only in oral form and in accordance with the patient's allergy profile.
Study: NCT04374253
Drug: Gantenerumab
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 participants who were in the active arm in the double blind part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W. Participants who are naive to gantenerumab treatment will be required to undergo the 3 step uptitration scheme before receiving target dose of open label gantenerumab, 510 mg SC, Q2W.
Study: NCT04374253
Drug: Gantenerumab
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 participants who have completed OLE part in the parent study (WN29922 or WN39658), will continue to receive open-label gantenerumab 510 mg SC, Q2W
Study: NCT05016778
Drug: GPRC5D-CAR-T
Normalized name: GPRC5D-CAR-T
DrugBank: OriCar-017 (DB17280)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.
Study: NCT06190145
Drug: Teriflunomide
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose of 7 mg once daily. Dose adjustments were made throughout the study based on individual platelet counts.
Study: NCT05067972
Drug: PF-07260437
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B7-H4 x CD3 bi-specific mAb
Study: NCT02127736
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05721300
Drug: NAs（EntecavirorTenofovirorTenofovir alafenamide） combined with interferon treatments
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NAs（EntecavirorTenofovirorTenofovir alafenamide） combine with interferon treatments for 48 weeks, and then continue with NAs treatment（EntecavirorTenofovirorTenofovir alafenamide）
Study: NCT05721300
Drug: NAs （EntecavirorTenofovirorTenofovir alafenamide） treatments
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients receive NAs（EntecavirorTenofovirorTenofovir alafenamide） treatment at least 48 weeks
Study: NCT00399295
Drug: Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg.
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05297929
Drug: Irbesartan Tablet
Normalized name: Irbesartan Tablets
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Irbesartan Oral administration on an empty stomach／fed condition
Study: NCT05995249
Drug: TAK-279
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-279 capsules
Study: NCT05995249
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz tablets
Study: NCT06212934
Drug: Estazolam
Normalized name: Estazolam
DrugBank: Estazolam (DB01215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take estazolam 1mg 30min prior to bedtime everyday. The course of treatment is two weeks.
Study: NCT05887479
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Toxin of Clostridium Botulinum
Study: NCT01240928
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Level 1: Exemestane - 25mg daily
Study: NCT01240928
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
Study: NCT05903040
Drug: Lasmiditan
Normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients using Lasmiditan 50-100-200 mg oral tablet to treat acute migraine attacks
Study: NCT05627752
Drug: Enzalutamide 40 MG
Normalized name: enzalutamide 40 MG
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adding Enzalutamide to Docetaxel chemotherapy
Study: NCT05627752
Drug: Docetaxel injection
Normalized name: docetaxel Injection
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel chemotherapy
Study: NCT00416429
Drug: medroxyprogesterone
Normalized name: Medroxyprogesterone
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04482244
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Liquid taken orally
Study: NCT05286164
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eltrombopag 150 mg QD for 8 weeks
Study: NCT05029609
Drug: Intranasal Foralumab Solution
Normalized name: influenza A virus (H1N1) antigen
DrugBank: Foralumab (DB16170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Aptar Unidose device will be used to deliver foralumab nasal solution intranasally. Foralumab nasal solution is prepackaged in a Type 1 glass vial inside the Unidose device.
Study: NCT06731231
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are glucose lowering agents used in the treatment of type 2 DM by improving glycemic control, weight reduction, blood pressure control and albuminuria. the use of SGLT2i as a cardiorenal protective tool may be of particular value in renal transplant patients due to the risk of multiple comorbidities such as diabetes and hypertension. Recently, sodium-glucose transport protein 2 inhibitors (SGLT2i) emerged as a new class of therapeutics with beneficial effects on both cardiovascular (CV) and kidney outcomes in patients with diabetic kidney disease, nondiabetic proteinuric chronic kidney disease (CKD), and heart failure with and without diabetes in patients with native kidneys
Study: NCT06143787
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days Oral rinsing following tooth extraction
Study: NCT05192382
Drug: Paltusotine
Normalized name: Paltusotine
DrugBank: Paltusotine (DB16277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paltusotine, tablets, once daily by mouth
Study: NCT05776004
Drug: CAL02
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CAL02 consists of a mixture of 2 liposomes and is a non-biological bacterial virulence neutralizer.
Study: NCT05905133
Drug: CBP-201
Normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT06219902
Drug: Elinzanetant (BAY3427080)
Normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of multiple doses of elinzanetant.
Study: NCT06219902
Drug: Placebo to elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06219902
Drug: Zopiclone
Normalized name: zopiclone
DrugBank: Zopiclone (DB01198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06219902
Drug: Placebo to zopiclone
DrugBank: Zopiclone (DB01198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06133478
Drug: NUV001 active cohort 1
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 participants will be assigned to receive active treatment
Study: NCT06133478
Drug: NUV001 active cohort 2
Normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 participants will be assigned to receive active treatment
Study: NCT06133478
Drug: NUV001 active cohort 3
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 participants will be assigned to receive active treatment
Study: NCT06133478
Drug: NUV001 active cohort 4
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 participants will be assigned to receive active treatment
Study: NCT04601883
Drug: Colchicine 0.5 MG
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention tablets are commercially available Colchicine Tiofarma
Study: NCT05458024
Drug: Vitamin D 2
Normalized name: VITAMIN D 25000UNT CAP
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300,000 international units (IUs) of Ergocalciferol in 6 50,000 IU capsules.
Study: NCT05458024
Drug: Vitamin D2 Placebo
Normalized name: vitamin D2
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert substance will be administered in 6 capsules indistinguishable from the 50,000 IU
Study: NCT04650581
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg PO QD days 1-21 every 28 days
Study: NCT04650581
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg IM cycle 1 days 1 and 15 followed by 500 mg IM day 1 q 28 days subsequent cycles
Study: NCT00002267
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05761704
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100 mg + clopidogrel 75 mg for 4 weeks post-LAAC; followed by aspirin/clopidogrel for 4-24 weeks post-LAAC; recommended long-term aspirin treatment after 24 weeks (clopidogrel can be used instead if aspirin is intolerant).
Study: NCT05380986
Drug: Camrelizumab combined with apatinib mesylate
Normalized name: mesylate
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200 mg, IVGTT D1, apatinib mesylate, once daily. The specific prescription is determined by the investigator. Continued use until disease progression, unacceptable toxicity, or withdrawal for other reasons.
Study: NCT05765825
Drug: serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab will be administered by intravenous infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, and clinical status.
Study: NCT05765825
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of serplulimab on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Study: NCT05765825
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) of 5 mg/mL/min on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Study: NCT05765825
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide will be administered intravenously at a dose of 100 mg/m\^2 on Days 1, 2 and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
Study: NCT04706130
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After treatment of the blood stage infection, enrolled participants will receive either no primaquine, a low dose of primaquine or a high dose of primaquine against liver parasites
Study: NCT04706130
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All enrolled participants will receive a 7-day treatment of artesunate ((2 mg/kg/day) to clear blood-stage parasites
Study: NCT04923893
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered SC.
Study: NCT04923893
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered orally.
Study: NCT04923893
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be administered orally.
Study: NCT04923893
Drug: Cilta-cel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilta-cel infusion will be administered.
Study: NCT04923893
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered intravenously.
Study: NCT05984173
Drug: Vitamin E application
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients received vitamin E inside the socket after extraction
Study: NCT03947775
Drug: 9-valent HPV vaccination
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil-9 is a novel, 9-valent HPV recombinant vaccine, which expands the coverage of oncogenic HPV types, with the addition of HPV types 31, 33, 45, 52, and 58 to the existing quadrivalent vaccine types. The addition of these five oncogenic types is estimated to improve cancer coverage to 90% (versus 70% for the quadrivalent vaccine) \[38\]. With its expanded coverage of oncogenic HPV types, its proven efficacy in primary prevention and its potential role in mitigating HGAIN recurrences.
Study: NCT04889599
Drug: BH009 (Docetaxel injection)
Normalized name: docetaxel Injection
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2
Study: NCT04889599
Drug: Docetaxel injection
Normalized name: docetaxel Injection
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg/m2
Study: NCT05777174
Drug: MB-102
Normalized name: MB-102 CD123 CAR
DrugBank: MB-102 CD123 CAR (DB17366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18.6 mg/mL in a 7.0 mL volume administered by intravenous injection over 30 - 60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 - 60 seconds
Study: NCT06010628
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous tenecteplase (0.25 mg/kg, a single bolus over 5 to 10 seconds, a maximum of 25 mg).
Study: NCT04304261
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 weeks of Canagliflozin(100mg/day) treatment
Study: NCT04304261
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12 weeks of Sitagliptin (100mg/day) treatment
Study: NCT00025753
Drug: rosiglitazone (Avandia)
Normalized name: rosiglitazone Oral Tablet [Avandia]
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no